缺血性卒中后的免疫抑制、感染与功能结局
本文综述卒中后免疫抑制与感染的流行病学、危险因素、病因、诊断、临床表现及潜在治疗。肺炎和尿路感染各约见于10%的患者,肺炎增加不良结局和死亡;预防性抗生素治疗未改善功能结局,免疫调节策略需兼顾脑内神经炎症并避免进一步组织损伤。
要点
- 卒中后神经炎症触发系统性免疫抑制,抗菌防御受损使患者易感感染。
- 肺炎和尿路感染各约发生于10%的卒中患者,肺炎增加不良结局和死亡。
- 预防性抗生素治疗未改善卒中后功能结局;免疫调节策略需避免加重脑组织损伤。
核心结论
- 卒中后免疫抑制由神经炎症触发,主要经自主神经系统过度激活介导,表现为淋巴细胞减少及固有和适应性免疫细胞功能障碍。
- 肺炎和尿路感染各约发生于10%的患者,肺炎增加不良结局和死亡,全身效应如低血压、发热、康复延迟被认为起关键作用。
- 预防性抗生素治疗未改善卒中后功能结局;免疫调节策略需兼顾缺血脑组织的神经炎症并避免进一步组织损伤。
- 实验研究发现了有前景的靶点,但尚未在卒中患者中研究;更好地理解病理生物学可能有助于开发优化方法。
研究设计与样本
- 综述,旨在描述卒中后免疫抑制及相关感染的流行病学、危险因素、病因、诊断、临床表现和潜在治疗。
主要发现
- 卒中后神经炎症启动,通过自主神经系统过度激活触发系统性免疫抑制。
- 免疫抑制表现为淋巴细胞减少以及固有和适应性免疫细胞功能障碍,抗菌防御受损。
- 肺炎和尿路感染各约发生于10%的患者;肺炎增加不良结局和死亡。
- 实验和临床数据提示系统性感染增强针对脑抗原的自身反应性免疫应答并负面影响结局,但缺乏令人信服的证据。
- 预防性抗生素治疗未改善卒中后功能结局;实验研究发现的靶点尚未在患者中研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke remains one of the main causes of mortality and morbidity worldwide. Immediately after stroke, a neuroinflammatory process starts in the brain, triggering a systemic immunodepression mainly through excessive activation of the autonomous nervous system. Manifestations of immunodepression include lymphopenia but also dysfunctional innate and adaptive immune cells. The resulting impaired antibacterial defenses render patients with stroke susceptible to infections. In addition, other risk factors like stroke severity, dysphagia, impaired consciousness, mechanical ventilation, catheterization, and older age predispose stroke patients for infections. Most common infections are pneumonia and urinary tract infection, both occur in ≈10% of the patients. Especially pneumonia increases unfavorable outcome and mortality in patients with stroke; systemic effects like hypotension, fever, delay in rehabilitation are thought to play a crucial role. Experimental and clinical data suggest that systemic infections enhance autoreactive immune responses against brain antigens and thus negatively affect outcome but convincing evidence is lacking. Prevention of poststroke infections by preventive antibiotic therapy did not improve functional outcome after stroke. Immunomodulatory approaches counteracting immunodepression to prevent stroke-associated pneumonia need to account for neuroinflammation in the ischemic brain and avoid further tissue damage. Experimental studies discovered interesting targets, but these have not yet been investigated in patients with stroke. A better understanding of the pathobiology may help to develop optimized approaches of preventive antibiotic therapy or immunomodulation to effectively prevent stroke-associated pneumonia while improving long-term outcome after stroke. In this review, we aim to characterize epidemiology, risk factors, cause, diagnosis, clinical presentation, and potential treatment of poststroke immunosuppression and associated infections.
引用
- Westendorp WF, Dames C, Nederkoorn PJ, et al. Immunodepression, Infections, and Functional Outcome in Ischemic Stroke. Stroke. 2022. PMID: 35341322. doi:10.1161/STROKEAHA.122.038867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。